Amneal Pharmaceuticals, Inc. Class A Common Stock (AMRX)vsViatris Inc (VTRS)
AMRX
Amneal Pharmaceuticals, Inc. Class A Common Stock
$12.26
+1.57%
HEALTHCARE · Cap: $3.80B
VTRS
Viatris Inc
$13.50
+1.05%
HEALTHCARE · Cap: $15.39B
Smart Verdict
WallStSmart Research — data-driven comparison
Viatris Inc generates 374% more annual revenue ($14.30B vs $3.02B). AMRX leads profitability with a 2.4% profit margin vs -24.6%. VTRS earns a higher WallStSmart Score of 50/100 (C-).
AMRX
Hold46
out of 100
Grade: D+
VTRS
Buy50
out of 100
Grade: C-
Intrinsic Value Comparison
Multi-model valuation · Graham Formula
Margin of Safety
-42.7%
Fair Value
$10.30
Current Price
$12.26
$1.96 premium
Intrinsic value data unavailable for VTRS.
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
No standout strengths identified
Growing faster than its price suggests
Reasonable price relative to book value
Areas to Watch
2.6% earnings growth
2.4% margin — thin
Premium valuation, high expectations priced in
ROE of -8.8% — below average capital efficiency
ROE of -21.1% — below average capital efficiency
Earnings declined 70.6%
Distress zone — elevated risk
Currently unprofitable
Comparative Analysis Report
WallStSmart ResearchBull Case : AMRX
Revenue growth of 11.5% demonstrates continued momentum.
Bull Case : VTRS
The strongest argument for VTRS centers on PEG Ratio, Price/Book. PEG of 0.14 suggests the stock is reasonably priced for its growth.
Bear Case : AMRX
The primary concerns for AMRX are EPS Growth, Profit Margin, P/E Ratio. A P/E of 54.9x leaves little room for execution misses. Thin 2.4% margins leave little buffer for downturns.
Bear Case : VTRS
The primary concerns for VTRS are Return on Equity, EPS Growth, Altman Z-Score.
Key Dynamics to Monitor
AMRX profiles as a value stock while VTRS is a turnaround play — different risk/reward profiles.
AMRX carries more volatility with a beta of 1.30 — expect wider price swings.
AMRX is growing revenue faster at 11.5% — sustainability is the question.
VTRS generates stronger free cash flow (551M), providing more financial flexibility.
Bottom Line
VTRS scores higher overall (50/100 vs 46/100). Both earn "Buy" and "Hold" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
Amneal Pharmaceuticals, Inc. Class A Common Stock
HEALTHCARE · DRUG MANUFACTURERS - SPECIALTY & GENERIC · USA
Amneal Pharmaceuticals, Inc. develops, licenses, manufactures, markets and distributes generic and specialty pharmaceutical products for various dosage forms and therapeutic areas. The company is headquartered in Bridgewater, New Jersey.
Viatris Inc
HEALTHCARE · DRUG MANUFACTURERS - SPECIALTY & GENERIC · USA
Viatris Inc. is an American global healthcare company headquartered in Canonsburg, Pennsylvania.
Visit Website →Compare with Other DRUG MANUFACTURERS - SPECIALTY & GENERIC Stocks
Want to dig deeper into these stocks?